Introduction
Many tumors possess tumor-specific antigens or, at least, antigens expressed at a higher level in neoplastic cells than that in normal cells (1) . It was observed that these tumor cells could be recognized by properly activated T lymphocytes (2, 3) . However, the autologous host is still unable to reject tumor because tumor cells are usually weak immunogenic and very inefficient in inducing tumor-specific T cells which play a key role in tumor rejection (4) (5) (6) . In addition, some tumor cells may secrete certain immunosuppressive factors to modify the host immune responses (7) . Therefore, failure of an antitumor immune response could also be related to the defects of immune regulation.
The generation of specific cytotoxic T cell responses is thought to depend on the help of activated CD4 ϩ T cells (8, 9) . In general, CD8 ϩ T cells destroy tumor cells directly, while CD4 ϩ T cells produce lymphokines that amplify the antitumor activity of CD8 ϩ T cells and activate other inflammatory cells (2) . Therefore, activation of both CD8 ϩ and CD4 ϩ T lymphocytes might lead to a more efficient immune Correspondence to: R.-H. Lin
Transmitting editor: G. Klein Received 13 January 1998, accepted 2 June 1998 response to destroy tumor cells. Indeed, both CD4 ϩ and CD8 ϩ T cells were required in antitumor immune responses induced by MHC class II and B7-1 gene transfected tumor cells (10, 11) . A similar result was also reported in the study of mouse melanoma cells that expressed significant levels of MHC class II antigen (12) . In that system, cells transfected with B7-1 and human melanoma-associated antigen were found to induce both CD4 ϩ and CD8 ϩ T cell responses which were required for tumor regression. During the early stages of tumor growth, only minimal death of tumor cells occurs and sufficient soluble tumor antigens may not be available for uptake by antigen-presenting cells (APC). Thus, it is difficult to turn on the tumor-reactive T h cells. As tumor growth progresses, soluble tumor antigens may be generated sufficiently. By this time, the tumor may have reached a threshold size against which any immune response may be impotent. Therefore, failure of the antitumor immune response could result from the inadequate activation of tumor-specific T h cells (8) . A number of studies have focused on the strategy of transducing tumor cells with cytokine genes (13, 14) . This strategy seeks to enhance the activation of tumor-specific lymphocytes by delivering a relevant cytokine which can substitute for the help of T cells at the site of the immunizing tumor. It was found that different cytokine gene-transfected tumors trigger different types of local antitumor responses, whose efficiency, however, is influenced by the type and dose of the cytokine, as well as by the cell type of the tumor. Thus, whether a cytokine is able to induce long-term tumor-specific immunity appears to be dependent on the experimental conditions and remains inconclusive (13) .
If we can use the helper activity of pre-existing T cells, we might be able to enhance the antitumor immune responses. In the present study, we immunized ovalbumin (OVA)-sensitized mice with OVA-pulsed P388 tumor cells which could cognate and reactivate pre-primed OVA-specific T cells. We clearly demonstrated that immunization with OVA-pulsed P388 cells in the presence of OVA-specific CD4 ϩ T cells could augment the generation of P388-specific cytotoxic T cells and inhibit the growth of subsequently challenged P388 cells. Both CD4 ϩ and CD8 ϩ T cells demonstrated tumor-specific cytotoxic activity in vitro; however, only CD8 ϩ T cells were able to inhibit the growth of challenged tumor in vivo. Thus, by cognating pre-existing foreign antigen-specific T h cells with tumor cells, antitumor immunity can be enhanced easily and effectively.
Methods

Mice and cells
DBA/2J mice were obtained from the animal breeding center of the National Cheng Kung University in Taiwan. Mice were maintained in the animal facility of the National Taiwan University. In all experiments the principles of laboratory animal care were followed under the guidance of the National Taiwan University, Animal Care and Use Committee. Mice (8-14 weeks old) were age and sex matched for each experiment. P388 cells (macrophage-like cells) and P815 cells (mastocytoma cells) were originally derived from syngeneic DBA/2 mice. P388 cells were maintained in RPMI 1640 medium supplemented with 10% FCS (Hyclone, Logan, UT) by repeating selection of the adherent P388 cells. Forty hours before being injected into mice, cells were re-cultivated in the AIM-V serum-free medium (Gibco/BRL, Grand Island, NY).
mAb
Hybridomas producing rat anti-mouse MHC II mAb M5/ 114.15.2, rat anti-mouse CD4 (L3T4) mAb GK1.5 (IgG2b) and rat anti-mouse CD8 (Lyt2) mAb 53-6.72 (IgG2a) were obtained from the ATCC (Rockville, MD). Purified rat Ig were purchased from PharMingen (San Diego, CA).
Priming and preparation of OVA-specific T cells Mice were primed s.c. with 50 µg OVA emulsified 1:1 with complete Freund's adjuvant (CFA) (Gibco/BRL Life Technologies) at the base of tail. Nine days later, OVA-primed T cells were prepared from the inguinal and popliteal lymph nodes of three mice. Briefly, after nylon wool column passage, lymph node cells were subsequently panned on the anti-MHC class II mAb (M5/114.15.2) coating plate to remove remaining Iapositive cells. The purity of T cells was Ͼ90% in the total cell population according to FACScan analysis (Becton Dickinson, Mountain View, CA).
Lymphocyte proliferation assay OVA-pulsed P388 cells were prepared by incubating P388 cells with 600 µg/ml of OVA for 16 h in vitro and then washed twice with HBSS. Thereafter, OVA-pulsed P388 cells were exposed to 9900 rad irradiation ( 137 Cs source irradiator, IBL-637; CIS Biointemational, France). The exposure dose of this radiation was found to be able to inhibit the proliferation, but not the substantial stimulator function of P388 cells. To stimulate OVA-primed T cells, we added different numbers of irradiated OVA-pulsed P388 cells to triplicate sets in Ubottomed microtiter plates (Costar, Cambridge, MA) and mixed with 10 5 OVA-primed T cells per well. The wells containing irradiated unpulsed P388 cells were used as the control group. Finally, proliferation was measured on the third day by adding 0.5 µCi [ 3 H]thymidine to the cell culture during the last 18 h.
Tumor-specific cell-mediated cytotoxicity
The tumor-specific cell-mediated cytotoxicity was measured by the JAM test (15) . Briefly, DBA/2 mice were sensitized with OVA by injection of 50 µg OVA in CFA in the base of the tail. Seven days later, mice were treated with one immunizing course of irradiated OVA-pulsed P388 cells. For each immunizing course, the OVA-sensitized mice were inoculated s.c. twice on their right flank with 5ϫ10 6 irradiated OVApulsed P388 cells at a 3-5 day interval. As control, an irrelevant antigen, cytochrome c, was used instead of OVA. At 7-10 days after immunization, 4ϫ10 6 Depletion of CD4 ϩ or CD8 ϩ T cell subsets in vitro by panning For depletion of CD4 ϩ or CD8 ϩ T cells, 5 ml 10 µg/ml of anti-CD4 mAb (GK1.5) or anti-CD8 mAb (53-6.72) in 0.05 M Tris buffer (pH 9.5) was coated on plates (1029; Falcon, Lincoln Park, NJ) by incubation at room temperature for 1 h. Thereafter, the antibody-coated plate was washed twice with HBSS to remove the excess mAb and blocked by RPMI 1640 containing 10% FCS at room temperature for 30 min. Spleen cells from the OVA-presensitized and OVA-pulsed P388 cells immunized mice were stimulated in vitro with irradiated P388 cells for 3 days, and then the activated cells were panned on the anti-CD8 or anti-CD4 mAb coating plate to deplete either CD4 ϩ or CD8 ϩ T cells. After incubation at room temperature for 1 h, the unbound cells were removed and immediately used as effector cells in the JAM test. The purity of both CD4 ϩ and CD8 ϩ T cells was found to be Ͼ90% in the CD3 ϩ T cell population according to FACScan analysis.
Induction of antitumor immunity in OVA-sensitized mice by immunization with OVA-pulsed P388 cells DBA/2J mice were presensitized s.c. twice with 50 µg OVA in CFA (tail) and 50 µg OVA in incomplete Freund's adjuvant (footpad) at a 2 week interval. At 7-10 days after the last injection of OVA, these mice were treated with two immunizing course of irradiated OVA-pulsed P388 cells at an 8-13 day interval as described above. Four days after the last injection of irradiated OVA-pulsed P388 cells, these mice were challenged s.c. on the left flank with 5-7ϫ10 6 viable P388 cells and the growth of challenged tumors was monitored. The diameters of tumors were measured with Vernier callipers, twice, at right angles and the tumor size was determined as tumor area which was calculated from the multiple of the perpendicular tumor diameters. Mice with tumor size Ͻ20 mm 2 at the end of observation were considered as tumor resistant. For the control group, irradiated unpulsed P388 cells were used instead of irradiated OVA-pulsed P388 cells in the immunization. Furthermore, to test the specificity of tumor rejection, 10 6 live P815 cells were used to replace P388 cells for tumor challenge.
Induction of antitumor immunity by adoptive transfer of OVAprimed lymph node cells together with OVA-pulsed P388 cells OVA-primed lymph node cells were prepared from pooled inguinal and popliteal lymph nodes of mice on day 7 after s.c. immunization of 50 µg OVA in CFA from tail. Thereafter, DBA/2 mice were injected with 1.3ϫ10 7 OVA-primed lymph node cells mixed with 5ϫ10 6 irradiated OVA-pulsed P388 cells in the footpad. Three days later, these mice were further injected with 5ϫ10 6 irradiated OVA-pulsed P388 cells in the footpad to complete one immunizing course. On day 4 after immunization, these mice were challenged s.c. on the right flank with 5ϫ10 6 viable P388 cells and the growth of challenged tumor was measured. For transfer of CD4-depleted OVA-primed lymph node cells, OVA-primed lymph node cells were panned on the anti-CD4 mAb coating plate to deplete CD4 ϩ T cells as described above. The depletion percentage of CD4 ϩ T cells was Ͼ90% according to FACScan analysis.
Depletion of CD4 ϩ or CD8 ϩ T cell subset in vivo DBA/2J mice were presensitized s.c. with 50 µg OVA in CFA from tail. Eight days after injection of OVA, these mice were treated with two immunizing course of irradiated OVA-pulsed P388 cells at an 8 day interval as described above. On day 1 and day 4 after the last inoculation of irradiated OVA-pulsed P388 cells, the treated mice were i.p. injected with the Protein G bead-purified anti-CD4 (mAb GK1.5, 0.2 mg/injection), anti-CD8 (mAb 53-6.72, 0.4 mg/injection), a combination of anti-CD4 and anti-CD8 (total of 0.6 mg/injection) or control antibody (rat Ig, 0.6 mg/injection). Depletion of each subsets was verified by flow cytometry analysis of peripheral blood lymphocytes on day 4 after the second injection of mAb. It was demonstrated that this procedure removed~80-90% of either population of T cells. On day 4 after the last inoculation of irradiated OVA-pulsed P388 cells, these mice were challenged s.c. on the left flank with 5ϫ10 6 viable P388 cells and the growth of challenged tumors was elevated.
Statistical analysis
Statistical significance was determined according to the Wilcoxon sign-rank test. P Ͻ 0.05 was considered significant.
Results
Antigen-presenting ability of P388 tumor cells
To determine the antigen-presenting ability of P388 cells, purified OVA-primed T cells from draining lymph nodes of mice immunized with OVA/CFA were stimulated with irradiated OVA-pulsed P388 cells and the proliferation of T cells in response to OVA was examined. It was shown that OVA-pulsed P388 cells stimulated a significant OVA-specific proliferative response to OVA-primed T cells (Fig. 1A ). Significant proliferation was also observed when OVA-primed T cells were cocultured with OVA in the presence of APC, but not in the absence of APC (Fig. 1B) . This indicated that the proliferative response stimulated by OVA-pulsed P388 cells was not due to the presentation of OVA by the contaminated APC in the purified OVA-primed T cell population. These results demonstrate that P388 cells can present OVA to activate in vivo primed OVA-specific T cells.
Induction of tumor-specific cytotoxic T cell responses in OVAsensitized mice by immunization with irradiated OVA-pulsed tumor cells
To evaluate whether the immunogenicity of P388 tumor cells could be enhanced by cognating tumor cells with pre-existing foreign antigen-specific T h cells, we sensitized mice with OVA in CFA to generate OVA-specific T cell responses. The OVAsensitized mice were then immunized with irradiated OVApulsed P388 cells. Spleen cells from the treated mice were stimulated with P388 cells in vitro for 3 days and the activated cells were subsequently tested for P388-specific cytotoxicity in the JAM assay. It was shown that mice receiving irradiated P388 cells only could not induce significant anti-P388 cytotoxic responses ( Fig. 2A) , whereas effector cells generated from the mice immunized with OVA and subsequently with OVApulsed P388 cells exhibited a significant anti-P388 cytotoxic activity. Because the cytotoxic cells did not lyse the syngeneic P815 cell line, it indicated that they were P388 specific. In the control group, the OVA-sensitized mice were immunized with either irradiated unpulsed P388 cells or, an irrelevant antigen, cytochrome c-pulsed P388 cells. The significant anti-P388 cytotoxic responses could be induced only in the mice presensitized with OVA followed by immunization with irradiated OVA-pulsed P388 cells, but could not be found in the mice presensitized with OVA followed by immunization with either irradiated unpulsed P388 cells or cytochrome cpulsed P388 cells (Fig. 2B) . These results suggested that anti-P388 cytotoxicity can be enhanced only when pre-primed T h cells were cognated with the matched foreign antigenpulsed P388 cells. Moreover, effector cells generated from the cytochrome c-sensitized and cytochrome c-pulsed P388 cells immunized mice also showed potent anti-P388 cytotoxic responses (data not shown). Taken together, it can be concluded that activation of pre-existing OVA-specific T cells with OVA-pulsed P388 tumor cells could enhance the generation of the P388 tumor-specific cytotoxic T cells.
Presensitization of OVA was essential for augmenting the induction of P388-specific cytotoxicity by immunization with OVA-pulsed P388 cells
In order to know whether the pre-existence of OVA-primed T cells was required in generation of anti-P388 cytotoxic T cells, we immunized mice with irradiated OVA-pulsed or with irrelevant control antigen, cytochrome c, pulsed P388 cells. It was shown that the mice immunized with irradiated OVApulsed P388 cells without presensitization of OVA mount only a marginal level of cytotoxic response. Moreover, immunization of irradiated OVA-pulsed P388 cells in the cytochrome c-sensitized mice did not induce significant P388-specific cytotoxicity (Fig. 3) . The anti-P388 cytotoxic response could be demonstrated only in OVA pre-primed mice followed by immunization with irradiated OVA-pulsed P388 cells.
Involvement of both CD4 ϩ and CD8 ϩ T cells in anti-P388 cytotoxicity in vitro
To determine which T cell subsets were responsible for the cytotoxic responses against P388 cells in vitro, spleen cells from mice immunized with OVA/CFA and subsequently with irradiated OVA-pulsed P388 cells were stimulated with P388 cells in vitro for 3 days. The activated cells were harvested and the CD4 ϩ or CD8 ϩ T cells were further depleted immediately before testing for the P388-specific cytotoxicity. The tumorspecific cytotoxicity assay showed that the depletion of the CD4 ϩ and CD8 ϩ subset of T cells decreases~20 and 50% of the anti-P388 cytotoxic activity at the highest effector:target ratio respectively (Fig. 4A) . These results indicated that both CD4 ϩ and CD8 ϩ T cells contributed to P388-specific killing in vitro. The tumor specific cytotoxicity can also be partially blocked by either anti-MHC class I or class II mAb (Fig. 4B) . The majority of the cells involved in the tumor cell killing was found to be MHC class I restricted; however, MHC class IIrestricted T cells did play a certain role in the responses.
Immunization of the OVA-sensitized mice with OVA-pulsed P388 cells could inhibit the growth of P388 tumor
In order to investigate whether the tumor-specific immune responses induced by cognating tumor cells with pre-existing OVA-specific T h cells could inhibit the growth of subsequently challenged tumor in vivo, we conducted the tumor growth inhibition assay. The OVA-sensitized mice were further immunized with either irradiated P388 cells or irradiated OVA-pulsed P388 cells and subsequently challenged with viable P388 or P815 cells. It was demonstrated that 15 of 19 mice immunized with irradiated OVA-pulsed P388 cells were tumor resistant, whereas only five of 17 mice immunized with irradiated P388 cells were tumor resistance (Table 1 ). These results indicated that effective antitumor immunity could not be generated by immunization with irradiated unpulsed P388 cells in the OVA-sensitized mice. To evaluate the specificity of tumor resistance, syngeneic P815 cells were used as control cells for challenge. It was shown that all of the treated mice challenged with P815 cells developed tumor very quickly (Table 1) . Taken together, these results clearly demonstrated that cognate and activation of pre-existing OVA-specific T cells via OVA presented by tumor cells could effectively enhance the tumor-specific resistance. Growth inhibition of P388 cells in mice immunized with OVApulsed P388 cells required the pre-existence of OVA-primed CD4 ϩ T h cells To determine whether the presensitization of OVA was required for the enhancement of P388 tumor resistance, we immunized DBA/2 mice with irradiated OVA-pulsed P388 cells without presensitization of OVA. It was observed that mice receiving irradiated OVA-pulsed P388 cells demonstrated only a marginal inhibition in the growth of P388 tumor cells as compared with those receiving irradiated P388 cells (Fig. 5A) . Moreover, the growth of P388 tumor cells was slightly inhibited, but not statistically significant, in mice immunized with irradiated P388 cells as compared with that in naive mice. These data indicated that immunization with either irradiated P388 cells or irradiated OVA-pulsed P388 cells could only slow down the growth of P388 cells at the beginning of tumor challenge, but could not inhibit it effectively. To directly examine the importance of OVA-primed T cells in the elevation of P388-specific immunity, we transferred OVA-primed lymph node cells to naive DBA/2 mice and simultaneously immunized these mice with irradiated OVA-pulsed P388 cells in the footpads. The treated mice were then further injected once with irradiated OVA-pulsed P388 cells and challenged with live P388 cells. As shown in Fig. 5(B) , the growth of P388 cells was markedly abrogated in mice receiving irradiated OVA-pulsed P388 cells together with OVA-primed lymph node cells. Moreover, there is a significant difference (P Ͻ 0.05) in tumor size between the mice immunized with irradiated P388 cells and mice receiving both OVA-primed lymph node cells and irradiated OVA-pulsed P388. In the control group, naive DBA/2 mice were injected with the mixture of OVA-primed lymph node cells and irradiated unpulsed P388 cells. The rate of tumor growth in these control mice was similar to that in mice injected with irradiated P388 cells only. This data also suggested that the a At 7-10 days after the last injection of OVA, mice were treated with two immunizing course at an 8-13 day interval. For each immunizing course, the OVA-sensitized mice were inoculated s.c. twice on their right flank with 5ϫ10 6 of irradiated P388 cells or irradiated OVA-pulsed P388 cells at a 3-5 day interval.
b Four days after the last immunization, these mice were challenged s.c. on the left flank with 5-7ϫ10 6 viable P388 cells or 10 6 viable P815 cells and the growth of challenged tumors was elevated.
c Significant difference (P Ͻ 0.05, Wilcoxon sign-rank test) was observed between OVA/CFA plus irradiated OVA-pulsed P388 cell immunized mice and OVA/CFA plus irradiated P388 cell immunized mice.
d Pooled data from two separate experiments. e Pooled data from three separate experiments.
inhibition of tumor growth in mice receiving irradiated OVApulsed P388 cells and OVA-primed lymph node cells was not due to the non-specific killing of P388 cells by OVA-primed lymph node cells. In addition, if mice were treated with irrelevant cytochrome c-primed T cells together with irradiated OVA-pulsed P388 cells, the subsequently challenged P388 cells also grew rapidly. It is possible that cytochrome c-primed lymph node cells could not be cognated and reactivated by OVA-pulsed P388 cells. To further confirm that the inhibition of P388 growth in mice receiving both OVA-primed lymph node cells and irradiated OVA-pulsed P388 cells was due to the reactivation of OVA-specific CD4 ϩ T h cells by OVA-pulsed tumor cells, we transferred CD4-depleted OVA-primed lymph node cells instead of OVA-primed lymph node cells into naive DBA/2 mice and simultaneously immunized these mice with irradiated OVA-pulsed P388 cells. As shown in Fig. 5(C) , depletion of CD4 ϩ T cells in OVA-primed lymph node cells completely abrogated P388 tumor resistance. This result strongly suggested that OVA-specific CD4 ϩ T h cells, but not OVA-specific CD8 ϩ T cells, play an important role in the enhancement of P388 tumor resistance in mice receiving both OVA-primed T cells and irradiated OVA-pulse P388 cells.
T cell subsets required for the growth inhibition of P388 cells in mice immunized with OVA/CFA and OVA-pulsed P388 cells
To analyze which T cell subset was responsible for the growth inhibition of P388 cells in the OVA/CFA and irradiated OVApulsed P388 cells immunized mice, we depleted either CD4 ϩ T cells, CD8 ϩ T cells or both, by in vivo antibody treatment before challenge of viable P388 cells. After injection of control antibodies, the inhibition of P388 tumor cell growth was not influenced. About 70% of the treated mice were tumor resistant, although the remaining 30% of the treated mice still develop tumor (accounting for a majority of the growth indicated in Fig. 6 ). The growth inhibition of P388 cells was completely abrogated in mice depleted of both CD4 ϩ and CD8 ϩ T cells (Fig. 6C) . The difference in tumor size between mice received control rat Ig and mice injected with both anti-CD4 and anti-CD8 mAb was statistically significant (P Ͻ 0.05, Wilcoxon sign-rank test). This data indicated that T cells are responsible for the rejection of P388 cells in mice immunized with OVA/CFA and irradiated OVA-pulsed P388 cells. Moreover, growth of P388 cells was also greatly enhanced (P Ͻ 0.05) in CD8-depleted mice as compared with the nondepleted control mice (Fig. 6B) . In contrast, tumor growth was only slightly enhanced, but not statistically significant (P Ͼ 0.2) in CD4-depleted mice (Fig. 6A) , suggesting that CD4 ϩ T cells play only a minor role in the tumor rejection. Taken together, these results indicated that P388 tumor resistance in mice immunized with OVA/CFA and OVA-pulsed P388 cells was primarily mediated by CD8 ϩ T cells.
Discussion
The generation of specific and systemic cytotoxic T cell responses is known to depend on sufficient help from activated CD4 ϩ T cells. It has been shown that the inability of the host to reject a tumor might be due to insufficient generation of tumor-specific T h cells (2, (8) (9) (10) (11) 16) , although it was also reported that the MHC class II -, B7-transfected tumor cells could stimulate allogenic cytotoxic T cells (17) or induce tumor rejection (18) in the absence of CD4 ϩ T cells. However, it is possible that CD4 ϩ T h cells are not necessary in inducing, but may serve to amplify the cytotoxic T cell response in these case. In our present investigation, we recruited and cognated tumor cells with OVA-primed T h cells by immunizing OVA-sensitized mice with irradiated OVApulsed cells. We demonstrated here that the immunogenicity of tumor cells was augmented, and both CD4 ϩ and CD8 ϩ tumor-specific cytotoxic T cells were induced. Moreover, the growth of the subsequently challenged tumor could be inhibited by CD8 ϩ T cells. According to Mitchison's hypothetical concept (19) , cellular cooperation in tumor immunity might augment antitumor resistance. In the past 30 years, various reports demonstrated that introduction of antigenic helper determinants to tumor cells by transfecting foreign antigen into tumor cells (20, 21) , infecting tumor cells with virus (22) (23) (24) , chemical coupling tumor cells with foreign antigen (25) (26) (27) or modifying tumor cells with hapten (28-32) could elevate the tumor-specific immune responses. However, the augmenting activity is not consistently high enough to reject tumor and the underlying mechanisms are still far from clear. In this investigation, our data directly support the involvement of the foreign antigenspecific T h cells in the augmentation of tumor resistance. The growth of P388 tumor cells could be inhibited by transferring OVA-primed T cells into naive mice and simultaneously immunizing these mice with OVA-pulsed P388 cells (Fig. 5B) . In contrast, depletion of CD4 ϩ T cells in OVA-primed lymph node cells completely abrogated the growth inhibition of P388 and tumor grew rapidly (Fig. 5C ). The generation of OVAspecific cytotoxic CD4 ϩ T cells by OVA/CFA priming is very unlikely but possible. However, naive P388 tumor cells could be killed in the absence of OVA antigen; the P388 tumorspecific killing observed in our study is not mediated by OVAspecific cytotoxic CD4 ϩ T cells.
It was claimed that the helper determinants, foreign antigen, must be carried on the same cell as the tumor-associated antigen (TAA) to increase the immunogenicity of tumor cells (27) (28) (29) . T h cells are usually stimulated by APC that presents exogenous antigen in the context of MHC class II molecules. Therefore, helper determinants coupled on tumor cells would have to be processed and presented by other APC. To ensure both foreign antigen and TAA were simultaneously presented in the context of MHC molecules on the same tumor cell, we directly pulsed tumor cells with a host pre-encountered foreign antigen. By cognating OVA-primed T cells with OVA-pulsed tumor cells, we have demonstrated that effective antitumor responses can be generated. Indeed, according to the previous investigations, potent and consistent tumor-specific immunity against primary tumors (28, 31) , metastasis (28) as well as leukemia cells (29, 30) could be observed in mice sensitized with hapten and immunized subsequently with hapten-modified tumor cells. Hapten can modify membrane proteins, such as MHC, on tumor cells. Thus, hapten might be carried on the same tumor cell as TAA to increase the immunogenicity of tumor cells. It is also possible that hapten can directly modify TAA and negatively influence the immunogenicity of TAA.
The binding of TCR to antigen-MHC complex on APC polarized the effector T cells to release lymphokines over the small area of the membrane in which the T cells and APC are in contact (33) (34) (35) (36) . In this way, the physiological concentration of lymphokines around APC is believed to be very high and the efficiency of cytokine activity decreased dramatically as the distance between the cells increased. Therefore, in our current study, we might create a microenvironment with significant amounts of lymphokines tightly around tumor cells to provide enough of a 'helper condition' for antitumor immunity in vivo. We have previously demonstrated that the immunogenicity of tumor cells could also be enhanced through the elevated expression of immune-related molecules on tumor cells (8) . Therefore, it is also possible that the interaction of primed OVA-specific T h cells with OVA-pulsed cells may enhance tumor immunogenicity by altering the expression of immune-related molecules on tumor cells. Memory T cells were demonstrated to reduce the stringency of the requirements for activation in comparison with that of the naive T cells (37, 38) . Memory T cells responded much better than naive T cells at a lower concentration of anti-CD3 or anti-CD2 mAb (39) . Moreover, memory T cells have a lower requirement for accessory co-stimulation than naive cells (40) . Therefore, it can be concluded that the priming of naive T cells was more difficult than the reactivation of memory T cells. In this current evaluation, we could not turn on detectable P388-specific cytotoxicity directly by using OVA-pulsed P388 cells in naive mice (Fig. 3) . Moreover, immunization of mice with irradiated OVA-pulsed P388 cells without presensitization of OVA could not induce effective tumor resistance (Fig. 5A ). This might be related to the inefficient priming of OVA-specific T h cells by OVA-pulsed P388 cells. In contrast, OVA-presenting P388 cells were capable of reactivating OVA-primed T h cells (Fig. 1A) . With the responses of OVA-specific T h cells tightly around the P388 tumor cells, mice were able to mount antitumor-specific T cell responses.
Every individual consists of some primed T h cells responding to certain environmental or infectious agents. If we can cognate and reactivate these pre-primed T h cells by antigen-pulsed tumor cells, we might be able to turn on tumorspecific T cells. Therefore, the method developed by our study has the potential to be applied in human tumor immunotherapy. The application of this system is not only limited in MHC class II ϩ tumors, but may also apply in certain MHC class II -tumors if we can induce the expression of MHC class II molecules by treating tumor cells with IFN-γ (41, 42) .
